Literature DB >> 8787881

Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis.

Y Lin1, W J Leach, W S Ammons.   

Abstract

As a consequence of their bactericidal actions, many antibiotics cause the release of endotoxin, a primary mediator of gram-negative sepsis. Bactericidal/permeability-increasing protein (BPI) has bactericidal activity and neutralizes endotoxin in vitro and in vivo. We sought to examine the effect of a recombinant N-terminal fragment of BPI (rBPI21) in conjunction with cefamandole, a cephalosporin antibiotic, in the treatment of Escherichia coli bacteremia and septic shock in rabbits. Cefamandole (100 mg/kg of body weight) was injected intravenously. This was followed by simultaneous 10-min infusions of E. coli O7:K1 (9 x 10(9) CFU/kg) and rBPI21 (10 mg/kg). rBPI21 was continuously infused for an additional 110 min at 10 mg/kg/h. The administration of rBPI21 in conjunction with the administration of cefamandole prevented the cefamandole-induced increase of free endotoxin in plasma, accelerated bacterial clearance, ameliorated cardiopulmonary dysfunction, and thereby, prevented death, whereas neither agent alone was protective in this animal model. The efficacy of the combined treatment with rBPI21 and cefamandole suggests a synergistic interaction between the two agents. The data indicate that rBPI21 may be useful in conjunction with traditional antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8787881      PMCID: PMC163058     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

Review 1.  Clinical relevance of antibiotic-induced endotoxin release.

Authors:  J M Prins; S J van Deventer; E J Kuijper; P Speelman
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

2.  Protective effect of a recombinant fragment of bactericidal/permeability increasing protein against carbohydrate dyshomeostasis and tumor necrosis factor-alpha elevation in rat endotoxemia.

Authors:  Y Lin; F R Kohn; A H Kung; W S Ammons
Journal:  Biochem Pharmacol       Date:  1994-04-29       Impact factor: 5.858

3.  Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of gram-negative sepsis: role of bactericidal properties.

Authors:  W S Ammons; F R Kohn; A H Kung
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

4.  Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability-increasing protein in experimental endotoxemia.

Authors:  F R Kohn; W S Ammons; A Horwitz; L Grinna; G Theofan; J Weickmann; A H Kung
Journal:  J Infect Dis       Date:  1993-11       Impact factor: 5.226

5.  Role of bactericidal permeability-increasing protein in the treatment of gram-negative pneumonia.

Authors:  C J Kelly; A C Cech; M Argenteanu; H Gallagher; J Shou; E Minnard; J M Daly
Journal:  Surgery       Date:  1993-08       Impact factor: 3.982

6.  Efficacy of a recombinant endotoxin neutralizing protein in rabbits with Escherichia coli sepsis.

Authors:  R Saladino; C Garcia; C Thompson; B Hammer; J Parsonnet; T Novitsky; G Siber; G Fleisher
Journal:  Circ Shock       Date:  1994-02

7.  Monocyte tissue factor induction by lipopolysaccharide (LPS): dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability-increasing protein.

Authors:  K Mészáros; S Aberle; R Dedrick; R Machovich; A Horwitz; C Birr; G Theofan; J B Parent
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

8.  Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria.

Authors:  H Gazzano-Santoro; K Mészáros; C Birr; S F Carroll; G Theofan; A H Horwitz; E Lim; S Aberle; H Kasler; J B Parent
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

9.  Bactericidal/permeability-increasing protein ameliorates acute lung injury in porcine endotoxemia.

Authors:  T J Vandermeer; M J Menconi; B P O'Sullivan; V A Larkin; H Wang; R L Kradin; M P Fink
Journal:  J Appl Physiol (1985)       Date:  1994-05

10.  A recombinant amino terminal fragment of bactericidal/permeability-increasing protein inhibits the induction of leukocyte responses by LPS.

Authors:  K Mészáros; J B Parent; H Gazzano-Santoro; R Little; A Horwitz; T Parsons; G Theofan; L Grinna; J Weickmann; P Elsbach
Journal:  J Leukoc Biol       Date:  1993-12       Impact factor: 4.962

View more
  8 in total

Review 1.  A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein.

Authors:  O Levy
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.

Authors:  A A Khan; L H Lambert; J S Remington; F G Araujo
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 3.  Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators.

Authors:  Eric L Campbell; Charles N Serhan; Sean P Colgan
Journal:  J Immunol       Date:  2011-10-01       Impact factor: 5.422

Review 4.  Of microbes and meals: the health consequences of dietary endotoxemia.

Authors:  Caleb J Kelly; Sean P Colgan; Daniel N Frank
Journal:  Nutr Clin Pract       Date:  2012-02-29       Impact factor: 3.080

5.  Host defense functions of proteolytically processed and parent (unprocessed) cathelicidins of rabbit granulocytes.

Authors:  Kol A Zarember; Seth S Katz; Brian F Tack; Laurence Doukhan; Jerrold Weiss; Peter Elsbach
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

Review 6.  Advances in sepsis therapy.

Authors:  Thomas Glück; Steven M Opal
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2.5 counteracts sepsis in rabbits.

Authors:  Sergio Bárcena-Varela; Guillermo Martínez-de-Tejada; Lukas Martin; Tobias Schuerholz; Ana Gloria Gil-Royo; Satoshi Fukuoka; Torsten Goldmann; Daniel Droemann; Wilmar Correa; Thomas Gutsmann; Klaus Brandenburg; Lena Heinbockel
Journal:  Exp Mol Med       Date:  2017-06-16       Impact factor: 8.718

8.  Pilot experience with opebacan/rBPI 21 in myeloablative hematopoietic cell transplantation.

Authors:  Eva Guinan; David E Avigan; Robert J Soiffer; Nancy J Bunin; Lisa L Brennan; Ilana Bergelson; Spencer Brightman; Al Ozonoff; Patrick J Scannon; Ofer Levy
Journal:  F1000Res       Date:  2015-12-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.